BioPharmSignal logoBioPharmSignal

Biotech News

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems (DCTH)Delcath SystemsEarnings

QUEENSBURY, N.Y. --(BUSINESS WIRE)--Apr. 23, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss

Open original release

Related news

DCTHDelcath Systems2026-05-07 12:00 EST

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

ICUIICU Medical2026-07-23 12:30 EST

ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call

EHCEncompass Health Corporation2026-07-09 20:30 EST

Encompass Health announces date of 2026 second quarter earnings call

TEVATeva Pharmaceutical Industries2026-06-18 20:30 EST

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

LEGNLegend Biotech Corporation2026-07-28 12:00 EST

Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

TMCITreace Medical Concepts2026-05-08 11:05 EST

Treace Medical Concepts Reports First Quarter 2026 Financial Results

RVMDRevolution Medicines2026-05-06 20:02 EST

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

DCTHDelcath Systems2026-05-26 20:01 EST

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

ICUIICU Medical2026-05-07 20:05 EST

ICU Medical Announces First Quarter 2026 Results

DNLIDenali Therapeutics2026-05-07 20:01 EST

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

View all latest news

Delcath Systems

Delcath Systems is a medical device and specialty oncology company focused on liver-directed cancer treatment. Its platform is built around regional therapy delivery for difficult tumors.

Recent company news

DCTHDelcath Systems2026-05-26 20:01 EST

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

DCTHDelcath Systems2026-05-12 12:00 EST

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

DCTHDelcath Systems2026-05-07 12:00 EST

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

DCTHDelcath Systems2026-05-07 11:00 EST

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

DCTHDelcath Systems2026-04-23 12:30 EST

Delcath Systems to Host First Quarter 2026 Earnings Call

Stock data

Close
11.94 USD
Market cap
363.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States